| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2021 ( Subtotal = -$2,363 ) |
| | 2021 | 2018 | ORGANIX INCORPORATED | 240 SALEM ST | WOBURN | MA | 01801-2029 | MIDDLESEX | USA | R44CA206723 | Targeting Breast Cancer Metastasis with Id1 | 000 | 3 | NIH | 2/13/2021 | -$2,363 |
|
| Issue Date FY: 2018 ( Subtotal = $743,502 ) |
| | 2018 | 2018 | ORGANIX INCORPORATED | 240 SALEM ST | WOBURN | MA | 01801-2029 | MIDDLESEX | USA | R44CA206723 | Targeting Breast Cancer Metastasis with Id1 | 000 | 3 | NIH | 7/27/2018 | $741,502 |
| | 2018 | 2018 | ORGANIX INCORPORATED | 240 SALEM ST | WOBURN | MA | 01801-2029 | MIDDLESEX | USA | R44CA206723 | Targeting Breast Cancer Metastasis with Id1 | 001 | 3 | NIH | 9/17/2018 | $2,000 |
|
| Issue Date FY: 2017 ( Subtotal = $809,827 ) |
| | 2017 | 2017 | ORGANIX INCORPORATED | 240 SALEM ST | WOBURN | MA | 01801-2029 | MIDDLESEX | USA | R44CA206723 | Targeting Breast Cancer Metastasis with Id1 | 001 | 2 | NIH | 6/29/2017 | $809,827 |
| | 2017 | 2016 | ORGANIX INCORPORATED | 240 SALEM ST | WOBURN | MA | 01801-2029 | MIDDLESEX | USA | R44CA206723 | Targeting Breast Cancer Metastasis with Id1 | 000 | 1 | NIH | 4/11/2017 | $0 |
|
| Issue Date FY: 2016 ( Subtotal = $178,146 ) |
| | 2016 | 2016 | ORGANIX, INC | 240 SALEM STREET | WOBURN | MA | 01801-2029 | MIDDLESEX | USA | R44CA206723 | Targeting Breast Cancer Metastasis with Id1 | 000 | 1 | NIH | 8/19/2016 | $178,146 |
| | 2016 | 2013 | ORGANIX, INC | 240 SALEM STREET | WOBURN | MA | 01801 | MIDDLESEX | USA | R43DA036289 | Cannabinoid Receptor Agonists for Treatment of Chronic Pain | 000 | 1 | NIH | 10/22/2015 | $0 |
|
| Issue Date FY: 2014 ( Subtotal = $0 ) |
| | 2014 | 2013 | ORGANIX, INC | 240 SALEM STREET | WOBURN | MA | 01801 | MIDDLESEX | USA | R43CA171415 | Targeting breast cancer metastasis with inhibitors of Id-1 | 000 | 1 | NIH | 5/9/2014 | $0 |
|
| Issue Date FY: 2013 ( Subtotal = $569,079 ) |
| | 2013 | 2013 | ORGANIX, INC | 240 SALEM STREET | WOBURN | MA | 01801-2029 | MIDDLESEX | USA | R43CA171415 | Targeting breast cancer metastasis with inhibitors of Id-1 | 000 | 1 | NIH | 5/1/2013 | $289,823 |
| | 2013 | 2013 | ORGANIX, INC | 240 SALEM STREET | WOBURN | MA | 01801-2029 | MIDDLESEX | USA | R43DA036289 | Cannabinoid Receptor Agonists for Treatment of Chronic Pain | 000 | 1 | NIH | 8/26/2013 | $279,256 |
|
| Issue Date FY: 2012 ( Subtotal = $581,271 ) |
| | 2012 | 2012 | ORGANIX, INC | 240 SALEM STREET | WOBURN | MA | 01801-2029 | MIDDLESEX | USA | R43DA035006 | THE FIRST REVERSIBLE RADIOLIGAND FOR THE HVMAT2 (3H)RESERPINE BINDING SITE | 000 | 1 | NIH | 8/30/2012 | $250,001 |
| | 2012 | 2012 | ORGANIX, INC | 240 SALEM STREET | WOBURN | MA | 01801-2029 | MIDDLESEX | USA | R43MH095315 | BENZODIAZEPINE ANALOGS AS NOVEL TREATMENTS FOR CATATONIA | 000 | 2 | NIH | 8/7/2012 | $331,270 |
|
| Issue Date FY: 2011 ( Subtotal = $791,072 ) |
| | 2011 | 2011 | ORGANIX, INC | 240 SALEM STREET | WOBURN | MA | 01801-2029 | MIDDLESEX | USA | R01DA005488 | SYNTHESIS OF DELTA9-TETRAHYDROCANNABINOL RELATED COMPOUNDS | 000 | 24 | NIH | 6/27/2011 | $337,617 |
| | 2011 | 2011 | ORGANIX, INC | 240 SALEM STREET | WOBURN | MA | 01801-2029 | MIDDLESEX | USA | R43MH095315 | BENZODIAZEPINE ANALOGS AS NOVEL TREATMENTS FOR CATATONIA | 000 | 1 | NIH | 9/16/2011 | $350,000 |
| | 2011 | 2011 | ORGANIX, INC | 240 SALEM STREET | WOBURN | MA | 01801-2029 | MIDDLESEX | USA | R03AI088542 | NOVEL 2'- AND 3'- BRANCHED CARBOCYCLIC NUCLEOSIDES WILL BE SYNTHESIZED AND EVALUA | 000 | 2 | NIH | 7/29/2011 | $103,455 |
|
| Issue Date FY: 2010 ( Subtotal = $787,183 ) |
| | 2010 | 2010 | ORGANIX, INC | 240 SALEM STREET | WOBURN | MA | 01801-2029 | MIDDLESEX | USA | R01DA005488 | SYNTHESIS OF DELTA9-TETRAHYDROCANNABINOL RELATED COMPOUNDS | 000 | 23 | NIH | 7/1/2010 | $348,059 |
| | 2010 | 2010 | ORGANIX, INC | 240 SALEM STREET | WOBURN | MA | 01801-2029 | MIDDLESEX | USA | R03AI088542 | NOVEL 2'- AND 3'- BRANCHED CARBOCYCLIC NUCLEOSIDES WILL BE SYNTHESIZED AND EVALUA | 000 | 1 | NIH | 9/21/2010 | $104,500 |
| | 2010 | 2010 | ORGANIX, INC | 240 SALEM STREET | WOBURN | MA | 01801-2029 | MIDDLESEX | USA | R03DA026593 | DEVELOPMENT OF CB2 AGONISTS FOR TREATMENT OF PAIN | 000 | 2 | NIH | 2/26/2010 | $238,343 |
| | 2010 | 2010 | ORGANIX, INC | 240 SALEM STREET | WOBURN | MA | 01801-2029 | MIDDLESEX | USA | R44DK065322 | INDOLE ANALOGS AS NOVEL APPETITE SUPPRESSANTS | 001 | 4 | NIH | 1/18/2010 | $96,281 |
| | 2010 | 2008 | ORGANIX, INC | 240 SALEM STREET | WOBURN | MA | 01801 | MIDDLESEX | USA | R44DK065322 | INDOLE ANALOGS AS NOVEL APPETITE SUPPRESSANTS | 000 | 4 | NIH | 12/24/2009 | $0 |
|
| Issue Date FY: 2009 ( Subtotal = $615,950 ) |
| | 2009 | 2009 | ORGANIX, INC | 240 SALEM STREET | WOBURN | MA | 01801-2029 | MIDDLESEX | USA | R01DA005488 | SYNTHESIS OF DELTA9-TETRAHYDROCANNABINOL RELATED COMPOUNDS | 001 | 22 | NIH | 6/19/2009 | $351,575 |
| | 2009 | 2009 | ORGANIX, INC | 240 SALEM STREET | WOBURN | MA | 01801-2029 | MIDDLESEX | USA | R03DA026593 | DEVELOPMENT OF CB2 AGONISTS FOR TREATMENT OF PAIN | 000 | 1 | NIH | 2/25/2009 | $264,375 |
| | 2009 | 2008 | ORGANIX, INC | 240 SALEM STREET | WOBURN | MA | 01801 | MIDDLESEX | USA | R01DA005488 | SYNTHESIS OF DELTA9-TETRAHYDROCANNABINOL RELATED COMPOUNDS | 000 | 21 | NIH | 12/8/2008 | $0 |
| | 2009 | 2006 | ORGANIX, INC | 240 SALEM STREET | WOBURN | MA | 01801 | MIDDLESEX | USA | R43DK071377 | NOVEL THC/ANANDAMIDE HYBRIDS AS APPETITE SUPPRESSANTS | 000 | 2 | NIH | 5/1/2009 | $0 |
|
| Issue Date FY: 2008 ( Subtotal = $1,950,273 ) |
| | 2008 | 2008 | ORGANIX, INC | 240 SALEM STREET | WOBURN | MA | 01801 | MIDDLESEX | USA | R43DK071377 | NOVEL THC/ANANDAMIDE HYBRIDS AS APPETITE SUPPRESSANTS | 001 | 2 | NIH | 9/23/2008 | $23,736 |
| | 2008 | 2008 | ORGANIX, INC | 240 SALEM STREET | WOBURN | MA | 01801 | MIDDLESEX | USA | R44DK065322 | INDOLE ANALOGS AS NOVEL APPETITE SUPPRESSANTS | 000 | 4 | NIH | 8/20/2008 | $394,714 |
| | 2008 | 2008 | ORGANIX, INC | 240 SALEM STREET | WOBURN | MA | 01801 | MIDDLESEX | USA | R01DA011542 | DISCOVERY OF NOVEL PHARMACOTHERAPIES: COCAINE DEPENDENCE | 000 | 10 | NIH | 3/3/2008 | $379,817 |
| | 2008 | 2008 | ORGANIX, INC | 240 SALEM STREET | WOBURN | MA | 01801 | MIDDLESEX | USA | R01DA008904 | ANANDAMIDE -- STRUCTURE/ACTIVITY RELATIONSHIPS | 000 | 13 | NIH | 2/28/2008 | $190,490 |
| | 2008 | 2008 | ORGANIX, INC | 240 SALEM STREET | WOBURN | MA | 01801 | MIDDLESEX | USA | R01DA005488 | SYNTHESIS OF DELTA9-TETRAHYDROCANNABINOL RELATED COMPOUNDS | 000 | 21 | NIH | 7/9/2008 | $351,575 |
| | 2008 | 2008 | ORGANIX, INC | 240 SALEM STREET | WOBURN | MA | 01801 | MIDDLESEX | USA | R43NS060210 | CB2 AGONISTS FOR TREATMENT OF NEUROPATHIC PAIN. | 000 | 1 | NIH | 7/25/2008 | $130,505 |
| | 2008 | 2008 | ORGANIX, INC | 240 SALEM STREET | WOBURN | MA | 01801 | MIDDLESEX | USA | R44MH063529 | INDOLE ANALOGS AS NOVEL TREATMENTS FOR OCD | 000 | 4 | NIH | 3/27/2008 | $479,436 |
|
| Issue Date FY: 2007 ( Subtotal = $1,847,184 ) |
| | 2007 | 2007 | ORGANIX, INC | 240 SALEM STREET | WOBURN | MA | 01801 | MIDDLESEX | USA | R44MH063529 | INDOLE ANALOGS AS NOVEL TREATMENTS FOR OCD | 000 | 3 | NIH | 4/21/2007 | $469,609 |
| | 2007 | 2007 | ORGANIX, INC | 240 SALEM STREET | WOBURN | MA | 01801 | MIDDLESEX | USA | R01DA005488 | SYNTHESIS OF DELTA9-TETRAHYDROCANNABINOL RELATED COMPOUNDS | 000 | 20 | NIH | 8/3/2007 | $358,750 |
| | 2007 | 2007 | ORGANIX, INC | 240 SALEM STREET | WOBURN | MA | 01801 | MIDDLESEX | USA | R01DA008904 | ANANDAMIDE -- STRUCTURE/ACTIVITY RELATIONSHIPS | 000 | 12 | NIH | 3/26/2007 | $194,377 |
| | 2007 | 2007 | ORGANIX, INC | 240 SALEM STREET | WOBURN | MA | 01801 | MIDDLESEX | USA | R01DA011542 | DISCOVERY OF NOVEL PHARMACOTHERAPIES: COCAINE DEPENDENCE | 000 | 9 | NIH | 3/7/2007 | $387,569 |
| | 2007 | 2007 | ORGANIX, INC | 240 SALEM STREET | WOBURN | MA | 01801 | MIDDLESEX | USA | R44DK065322 | INDOLE ANALOGS AS NOVEL APPETITE SUPPRESSANTS | 000 | 3 | NIH | 9/1/2007 | $436,879 |
|
| Issue Date FY: 2006 ( Subtotal = $1,709,943 ) (Continued on the next page) |
| | 2006 | 2006 | ORGANIX, INC | 240 SALEM STREET | WOBURN | MA | 01801 | MIDDLESEX | USA | R43DK071377 | NOVEL THC/ANANDAMIDE HYBRIDS AS APPETITE SUPPRESSANTS | 000 | 2 | NIH | 7/25/2006 | $244,419 |
|
